ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by ENDRA Life Sciences Inc. on February 3, 2021, reporting an event that occurred on February 2, 2021. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Ann Arbor, Michigan. Its common stock (NDRA) and warrants (NDRAW) are listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a regulatory compliance event regarding the Company's stock listing status.
Material Changes
The primary material event reported is the Company regaining compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. The Company received written notice from Nasdaq confirming that its common stock closing bid price was $1.00 per share or greater for at least ten consecutive business days, from January 15, 2021, to February 1, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks, contingencies, or unusual items are disclosed in this report other than the prior non-compliance with the minimum bid price requirement which has now been resolved.
Key Facts for Investor Verification
- Verify the current trading status of NDRA and NDRAW on The Nasdaq Stock Market LLC.
- Confirm the Company's continued compliance with Nasdaq minimum bid price requirements following this notice.
- Review subsequent filings for any financial updates, as this 8-K contains no financial performance data.